Kura Oncology (NASDAQ:KURA) Given "Overweight" Rating at Cantor Fitzgerald

Kura Oncology (NASDAQ:KURA - Get Free Report)'s stock had its "overweight" rating reissued by equities research analysts at Cantor Fitzgerald in a research report issued on Thursday,Benzinga reports.

Several other research firms have also recently commented on KURA. Mizuho lowered their target price on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, May 19th. Barclays lowered their target price on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Wall Street Zen cut Kura Oncology from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Wedbush reissued an "outperform" rating and set a $36.00 target price on shares of Kura Oncology in a research note on Friday, June 20th. Finally, UBS Group lowered their target price on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Kura Oncology presently has an average rating of "Moderate Buy" and an average target price of $24.50.

Kura Oncology Trading Down 1.0%

NASDAQ KURA traded down $0.06 on Thursday, reaching $5.67. 3,334,744 shares of the company were exchanged, compared to its average volume of 1,243,263. The business's fifty day moving average price is $6.17 and its 200 day moving average price is $7.14. The stock has a market capitalization of $490.85 million, a P/E ratio of -2.70 and a beta of 0.40. The company has a current ratio of 8.07, a quick ratio of 8.07 and a debt-to-equity ratio of 0.02. Kura Oncology has a fifty-two week low of $5.41 and a fifty-two week high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million during the quarter, compared to the consensus estimate of $39.08 million. Analysts forecast that Kura Oncology will post -2.44 earnings per share for the current year.

Institutional Trading of Kura Oncology

A number of large investors have recently made changes to their positions in the company. BVF Inc. IL boosted its position in shares of Kura Oncology by 202.0% in the 1st quarter. BVF Inc. IL now owns 7,754,129 shares of the company's stock valued at $51,177,000 after purchasing an additional 5,186,660 shares during the period. Armistice Capital LLC boosted its position in shares of Kura Oncology by 13.3% in the 1st quarter. Armistice Capital LLC now owns 6,572,000 shares of the company's stock valued at $43,375,000 after purchasing an additional 772,000 shares during the period. Vanguard Group Inc. boosted its position in shares of Kura Oncology by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company's stock valued at $32,658,000 after purchasing an additional 129,337 shares during the period. RA Capital Management L.P. acquired a new stake in shares of Kura Oncology in the 4th quarter valued at about $38,769,000. Finally, Millennium Management LLC boosted its position in shares of Kura Oncology by 180.1% in the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock valued at $20,618,000 after purchasing an additional 1,521,954 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.